Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with AI as first-line treatment for recurrent or metastatic soft tissue sarcoma
ChiCTR1800019077Phase 2Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Nov 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, doxorubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival. Started Nov 2018; status: recruiting.
02
Drugs
anlotinibdoxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR1800019077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019077.